Quest Diagnostics vs Roivant Sciences
Quest Diagnostics (DGX), health care, and Roivant Sciences (ROIV), health care, side by side on market value, valuation, margins, balance sheet and price change. Higher and lower are marked; neither is called better.
Quest Diagnostics and Roivant Sciences are valued at about the same: $28.2B and $28B. Quest Diagnostics's operating margin in its latest fiscal year was 14.1% and Roivant Sciences's -6236%. Over the past year Quest Diagnostics's share price has moved +41.5% and Roivant Sciences's +88.2%.
Key facts
- Quest Diagnostics market value
- $28.2B
- Roivant Sciences market value
- $28B
- Quest Diagnostics P/E
- 26.1
- Quest Diagnostics revenue
- $11BFY to 2025-12-31
- Roivant Sciences revenue
- $8.3MFY to 2026-03-31
- Superinvestors holding both
- 0
Market values as of .
| Measure | Quest Diagnostics | Roivant Sciences |
|---|---|---|
| Sector | Health Care | Health Care |
| Country | ||
| Fiscal year ends | 2025-12-31 | 2026-03-31 |
| Size | ||
| Market cap | $28.2Bhigher | $28Blower |
| Revenue | $11Bhigher | $8.3Mlower |
| Earnings | $992Mhigher | -$299.8Mlower |
| Employees | 60,000higher | 721lower |
| Total assets | $16.2Bhigher | $5.7Blower |
| Valuation | ||
| P/E | 26.1 | — |
| P/S | 2.6lower | 3396higher |
| P/B | 3.7 | — |
| Dividend yield | 1.29% | — |
| Profitability | ||
| Operating margin | 14.1%higher | -6236%lower |
| Balance sheet | ||
| Net assets | $7.2Bhigher | $4.5Blower |
| Total liabilities | $8.9Bhigher | $416.3Mlower |
| Total debt | $5.7B | — |
| Cash on hand | $420Mlower | $1.4Bhigher |
| Price change | ||
| Today | -2.23%lower | +0.26%higher |
| 1 year | +41.5%lower | +88.2%higher |
Market value, P/E, P/B, dividend yield and price changes are from live quotes (Yahoo Finance; prices may be delayed 15 minutes or more). Revenue, earnings, operating margin and the balance-sheet figures are from each company's latest annual report filed with the SEC (collected 2026-11-12); a company that reports in another currency is converted to US dollars at the exchange rate of that day. P/S sets today's market value against the latest fiscal year's revenue. “Higher” and “lower” compare the two numbers only; a higher P/E or more debt is not better. Dividend yield and P/B are shown only for companies based in the US. A dash means no figure is on file.
Which superinvestors hold them
From each tracked investor's latest 13F filing. A 13F lists long positions in US-listed shares at a quarter end, filed up to 45 days later.
Both (0)
None of the tracked investors.
Quest Diagnostics only (3)
Roivant Sciences only (6)
- Andrew Spokes4.1%
- David Einhorn1.9%
- Lee Ainslie0.9%
- Julian and Felix Baker0.8%
- Andreas Halvorsen0.6%
- Steve Cohen0.2%
Percentages are each holding's share of that investor's reported portfolio. Who owns DGX · Who owns ROIV
More on Quest Diagnostics
Further comparisons
Quest Diagnostics against its closest peers
Roivant Sciences against its closest peers
Learn
Questions and answers
Which is bigger, Quest Diagnostics or Roivant Sciences?
By market value, Quest Diagnostics is the larger: $28.2B against $28B for Roivant Sciences. By revenue in its latest fiscal year, Quest Diagnostics is the larger: $11B against $8.3M for Roivant Sciences.
Which has the higher operating margin?
Quest Diagnostics: 14.1%, against -6236% for Roivant Sciences. Operating margin is operating income as a share of revenue in the latest fiscal year.
Which superinvestors own both Quest Diagnostics and Roivant Sciences?
None of the tracked superinvestors holds both in their latest 13F filing. 3 hold Quest Diagnostics and 6 hold Roivant Sciences.
Cite this page
Funkfolio, “Quest Diagnostics vs Roivant Sciences”, data as of 18 November 2026. https://funkfolio.com/compare/dgx-vs-roiv
Underlying data: Yahoo Finance quotes; SEC annual reports collected 2026-11-12; 13F filings.